Acrivon Therapeutics stockholders approve 3 million share increase to equity plan
At its June 17, 2026 annual meeting, Acrivon Therapeutics stockholders approved an amended and restated 2022 Equity Incentive Plan that adds 3,000,000 shares, bringing the total reserve to 8,606,723 shares. They also re-elected two Class I directors, ratified PricewaterhouseCoopers LLP as auditor for 2026, and the plan's share reserve will rise automatically each January 1 through 2032. The plan allows equity awards to employees, non-employee directors and consultants, so the larger reserve affects the potential share count for existing holders.
Key points
- Equity plan: total reserve of 8,606,723 shares, including a 3,000,000-share increase; approved with 20,546,400 for and 3,757,400 against
- Annual automatic increase on January 1 through 2032 equal to 5% of fully diluted shares outstanding (including pre-funded warrants) at the prior December 31, unless the Board sets a lower amount
- Directors: Michael Tomsicek (24,020,408 for) and Charles Baum (23,657,074 for) elected as Class I directors until the 2029 annual meeting
- Quorum of 31,336,993.43 shares, or 73.21% of shares entitled to vote as of the April 23, 2026 record date
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on June 17, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.